Pharmaceuticals 2011, 4(11), 1488-1502; doi:10.3390/ph4111488
Article

Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins

1 Laboratory of Cell Biology, Institute of Biology and Ecology, Faculty of Sciences, P.J. Šafárik University, 040 01 Košice, Slovak Republic 2 Geriatric Nursing Clinic, Faculty of Medicine, P.J. Šafárik University, 040 01 Košice, Slovak Republic 3 Department of Pharmacology, Faculty of Medicine, P.J. Šafárik University,040 01 Košice, Slovak Republic
* Author to whom correspondence should be addressed.
Received: 1 September 2011; in revised form: 1 November 2011 / Accepted: 7 November 2011 / Published: 10 November 2011
(This article belongs to the Special Issue Hsp90 Inhibitors)
PDF Full-text Download PDF Full-Text [322 KB, uploaded 10 November 2011 12:24 CET]
Abstract: In this study we have focused on the response of SKBR-3 cells to both single 17-DMAG treatment as well as its combination with photodynamic therapy with hypericin. Low concentrations of 17-DMAG without any effect on survival of SKBR-3 cells significantly reduced metabolic activity, viability and cell number when combined with photodynamic therapy with hypericin. Moreover, IC10 concentation of 17-DMAG resulted in significant increase of SKBR-3 cells in G1 phase of the cell cycle, followed by an increase of cells in G2 phase when combined with photodynamic therapy. Furthermore, 17-DMAG already decreased HER2, Akt, P-Erk1/2 and survivin protein levels in SKBR-3 cells a short time after its application. In this regard, 17-DMAG protected also SKBR-3 cells against both P-Erk1/2 as well as survivin upregulations induced by photodynamic therapy with hypericin. Interestingly, IC10 concentration of 17-DMAG led to total depletion of Akt, P-Erk1/2 proteins and to decrease of survivin level at 48 h. On the other hand, 17-DMAG did not change HER2 relative expression in SKBR-3 cells, but caused a significant decrease of HER2 mRNA in MCF-7 cells characterized by low HER2 expression. These results show that targeting HSP90 client proteins increases the efficiency of antineoplastic effect of photodynamic therapy in vitro.
Keywords: hypericin-PDT; 17-DMAG; HSP90

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Solár, P.; Chytilová, M.; Solárová, Z.; Mojžiš, J.; Ferenc, P.; Fedoročko, P. Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins. Pharmaceuticals 2011, 4, 1488-1502.

AMA Style

Solár P, Chytilová M, Solárová Z, Mojžiš J, Ferenc P, Fedoročko P. Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins. Pharmaceuticals. 2011; 4(11):1488-1502.

Chicago/Turabian Style

Solár, Peter; Chytilová, Mária; Solárová, Zuzana; Mojžiš, Ján; Ferenc, Peter; Fedoročko, Peter. 2011. "Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins." Pharmaceuticals 4, no. 11: 1488-1502.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert